NDA 018679 · Dr Reddys Labs SA
Trimethoprim
Trimethoprim · Oral · Dihydrofolate Reductase Inhibitor Antibacterial
Last checked: Nov 19, 2026Latest source record: Aug 11, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Jul 30, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
259
71 Phase 3, 36 recruiting
FAERS reports
11,863
10,877 serious, 1,558 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 26, 2024.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, USP and other antibacterial drugs, trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 1982 Original approval
1 products under this application
- TRIMETHOPRIM · TRIMETHOPRIM 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Trimethoprim" as an intervention, any sponsor and status, largest first.
- Etiology, Prevention and Treatment of Neonatal Infections in the CommunityPivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00198627 · 16,359 participants · Start Dec 2003 · Primary completion Sep 2007
Drug: Co-Trimoxazole; TMP-SMZ · For: Bacterial Infection; Infectious Disease
Sites: Dhaka, Bangladesh
- Study to Improve Survival Among HIV-Exposed Infants in BotswanaPivotal-lookingCompleted
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT01229761 · 3,724 participants (planned) · Start May 2011 · Primary completion Mar 2015
Drug: cotrimoxazole prophylaxis; cotrimoxazole placebo · For: HIV Infections; Neutropenia; Anemia
Sites: Gaborone, Botswana; Lobatse, Botswana; Molepolole, Botswana
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/SulfamethoxazolePivotal-lookingStatus unknown
Umeå UniversityAcademic, hospital or other
NCT02734732 · 2,800 participants (planned) · Start Apr 2015 · Primary completion Apr 2020
Drug: Trimethoprim/Sulfamethoxazole; Ciprofloxacin · For: Prostate Infection
Sites: Östersund, Sweden; Sundsvall, Sweden; Ängelholm, Sweden · 5 sites in all
- A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000748 · 2,500 participants
Drug: Sulfamethoxazole-Trimethoprim · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: San Francisco, California; Stanford, California; Denver, Colorado · 24 sites in all
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe PneumoniaPivotal-lookingCompleted
King George's Medical UniversityAcademic, hospital or other
NCT00396526 · 2,000 participants · Start Apr 2004
Drug: Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days. · For: Non-Severe Pneumonia; Under-Fives; Children
Sites: Lucknow, India
- Computer Stop Order Alert to Prevent Concurrent Prescribing of Trimethoprim/Sulfamethoxazole and WarfarinPivotal-lookingTerminated
University of PennsylvaniaAcademic, hospital or other
NCT00870298 · 1,971 participants · Start Aug 2006 · Primary completion Jan 2007
Drug: Trimethoprim/Sulfamethoxazole and Warfarin · For: Prescribers' Drug Orders
- Cotrimoxazole Prophylaxis in Severely Malnourished ChildrenPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00934492 · 1,781 participants · Start Nov 2009 · Primary completion Apr 2014
Drug: Cotrimoxazole dispersible tablet; Placebo dispersible tablet · For: Nutrition Disorders; Life-threatening Infection
Sites: Kilifi, Kenya; Malindi, Kenya; Mombasa, Kenya · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea977
- off label use959
- headache910
- diarrhoea876
- malaise870
- drug ineffective801
- dyspnoea763
- pyrexia749
- vomiting746
- fatigue683
- rash633
- dizziness632
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 99 |
| 2005 | 126 |
| 2006 | 139 |
| 2007 | 172 |
| 2008 | 161 |
| 2009 | 209 |
| 2010 | 238 |
| 2011 | 344 |
| 2012 | 430 |
| 2013 | 443 |
| 2014 | 603 |
| 2015 | 677 |
| 2016 | 722 |
| 2017 | 541 |
| 2018 | 848 |
| 2019 | 931 |
| 2020 | 877 |
| 2021 | 852 |
| 2022 | 842 |
| 2023 | 782 |
| 2024 | 756 |
| 2025 | 625 |
| 2026 | 445 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trimethoprim (Trimethoprim)
2024 spending
$10.2M
Beneficiaries
54,995
186,969 claims
Per beneficiary
$185
$1.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,041,562 |
| 2021 | $4,166,076 |
| 2022 | $9,056,631 |
| 2023 | $9,528,512 |
| 2024 | $10,161,642 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.
Hadidi MF, Alhamami N, Alhakami M, et al. · World J Urol 2024 · Systematic Review, Network Meta-Analysis
- Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
Stern A, Green H, Paul M, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prophylaxis Options in Children With a History of Recurrent Urinary Tract Infections: A Systematic Review.
Gkiourtzis N, Stoimeni A, Glava A, et al. · Pediatrics 2024 · Systematic Review, Meta-Analysis
- Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis.
Prosty C, Hanula R, Levin Y, et al. · Clin Infect Dis 2023 · Meta-Analysis, Systematic Review
- Trimethoprim-associated hyperkalaemia: a systematic review and meta-analysis.
Faré PB, Memoli E, Treglia G, et al. · J Antimicrob Chemother 2022 · Meta-Analysis, Systematic Review
- Trimethoprim alone.
Clark AJ, Mouchizadeh J, Faunch R, et al. · Lancet 1980 · Case Reports, Clinical Trial
Sponsor: Dr Reddys Labs SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.